Evotec and Bristol Myers Squibb agreement will bolster treatments for neurodenerative diseases
A licensing agreement between Evotec SE and Bristol Myers Squibb Company (BMS) that will ‘bolster a pipeline of programmes targeting several neurodegenerative conditions’ was announced today (July 11).